Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Polynovo ( (AU:PNV) ) is now available.
PolyNovo announced a live-streamed presentation of its FY25 results, scheduled for 25 August. The presentation will provide insights into the company’s performance and future plans, potentially impacting its operations and market positioning. Shareholders and analysts are invited to participate and ask questions, highlighting the company’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive ASX 200 medical technology company based in Melbourne, Australia. It specializes in products that simplify the management of acute complex wounds, offering innovative solutions for improved patient outcomes across various wound types. The company has treated over 70,000 patients in 46 countries and is focused on growth through new products, indications, and market expansion.
Average Trading Volume: 2,104,479
Technical Sentiment Signal: Sell
Current Market Cap: A$811.7M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.